LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Alexander Stratigos, M.G. Fury, Michael R. Migden et al.|Annals of Oncology|2020

Cited by 14